May. 9 at 1:47 AM
$CMPS The Only Psychedelic Play That Matters 🧠🔬
COMP360 is the first classic psychedelic to hit highly statistically significant results across TWO Phase 3 trials, 1,000+ patients. Proven.
FDA just granted rolling NDA review + Commissioner’s Priority Voucher, shortened 1-2 month review timeline once filed.
Jefferies just upgraded to Strong-Buy. Morgan Stanley Overweight. Oppenheimer
$20 target. B.Riley says Q3 durability data could drive 50%+ upside.
$ATAI $PBM $DFTX caught the EO bounce.
$CMPS has the FDA momentum, the data, and the institutional backing. One clear leader in this space.
NFA. 🚀 Disclaimer - AI 🤖
